Linked Life Data

2528599

Source:http://linkedlifedata.com/resource/pubmed/id/2528599

Statements in which the resource exists as a subject.
PredicateObject
rdf:type
lifeskim:mentions
pubmed:issue
5
pubmed:dateCreated
1989-10-18
pubmed:abstractText
A tumor-specific immunotherapy model was established utilizing vaccinia virus (VV) in the consideration of clinical application, in which we assessed the significance of priming of hosts with VV to induce in vivo anti-tumor immunity. C3H/HeN mice were pretreated with cyclophosphamide (Cy) to eliminate non-specific suppressor T cell activity and subsequently inoculated (primed) subcutaneously (s.c.) with 10(7)PFU of VV, leading to augmented induction of VV-reactive helper T (VV-Th) cell activities. Four weeks later, the mice were inoculated intradermally (i.d.) with syngeneic X5563 myeloma cells. Six days after the tumor cell inoculation, 5 X 10(7)PFU of VV was injected into the tumor mass 3 times at 2-day intervals. Seven of 10 mice which had received VV-priming and subsequent VV-injection into the tumor mass exhibited complete tumor regression. On the contrary, mice which had received mere intratumoral VV-injection in the absence of VV-priming failed to exhibit appreciable tumor regression. Mice (regressor mice) whose tumor had completely regressed by the above VV-immunotherapy were shown to have acquired systemic anti-tumor immunity which was confirmed by a challenge with syngeneic tumor cells after the tumor regression. In vitro analysis of these immune mice revealed that potent tumor-specific cytotoxic T lymphocyte (CTL) responses were preferentially induced, but with no detectable anti-tumor antibody responses. Such a potent tumor specific immunity was not observed in mice which had received intratumoral VV-injection in the absence of VV-priming.(ABSTRACT TRUNCATED AT 250 WORDS)
pubmed:language
jpn
pubmed:journal
pubmed:citationSubset
IM
pubmed:status
MEDLINE
pubmed:month
May
pubmed:issn
0021-4671
pubmed:author
pubmed:issnType
Print
pubmed:day
20
pubmed:volume
24
pubmed:owner
NLM
pubmed:authorsComplete
Y
pubmed:pagination
1007-14
pubmed:dateRevised
2011-7-28
pubmed:meshHeading
pubmed:year
1989
pubmed:articleTitle
[Significance of priming of hosts with virus in the tumor-specific immunotherapy model utilizing virus-reactive helper T cell activity].
pubmed:publicationType
Journal Article, English Abstract